{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:18:20Z","timestamp":1783588700025,"version":"3.55.0"},"reference-count":58,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,2,6]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of morbidity and mortality due to chronic liver disease. There is an extensive body of evidence focusing on pharmacotherapy for MASLD. Reviews on the topic have been largely limited to the efficacy of select agents, subgroups or outcomes. The current is a protocol for a comprehensive systematic review and network meta-analysis (NMA) evaluating the efficacy of examined pharmaceutical interventions in improving hepatic outcomes of MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>MEDLINE, Scopus, Web of Science, the Cochrane Library database and multiple trial registries will be searched for clinical trials on MASLD pharmacotherapy. Histological, radiological and paraclinical outcomes will be considered along with safety and tolerability. Screening and data extraction will be conducted by pairs of independent reviewers. Risk of bias (RoB) will be assessed using the Cochrane RoB 2 tool. Pairwise random-effects meta-analyses will be conducted followed by random-effects frequentist NMAs\u2014according to the length of intervention\u2014for each outcome in clinically distinct MASLD subgroups. Other effect moderators will be examined in subgroup analyses and meta-regression. Certainty of evidence will be assessed using the Grading of Recommendations Assessment, Development and Evaluation and Confidence in Network Meta-Analysis approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval was waived (Alborz University of Medical Sciences; approval ID: IR.ABZUMS.REC.1404.121) as no new data will be generated. Information from published records will be used in compliance with their Copyright agreements. Results will be submitted for peer review and publication in a scientific journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD420251125615.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-111933","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T10:55:32Z","timestamp":1775645732000},"page":"e111933","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of pharmacological interventions for hepatic outcomes of metabolic dysfunction-associated steatotic liver disease: protocol for systematic review and network meta-analysis"],"prefix":"10.1136","volume":"16","author":[{"given":"Kiavash","family":"Semnani","sequence":"first","affiliation":[{"name":"Social Determinant of Health Research Center, Alborz University of Medical Sciences, Karaj, The Islamic Republic of Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farbod","family":"Semnani","sequence":"additional","affiliation":[{"name":"National Center for Health Insurance Research, Tehran, The Islamic Republic of Iran"},{"name":"School of Medicine, Tehran University of Medical Sciences, Tehran, The Islamic Republic of Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Sahab","family":"Aarabi","sequence":"additional","affiliation":[{"name":"National Center for Health Insurance Research, Tehran, The Islamic Republic of Iran"},{"name":"School of Medicine, Tehran University of Medical Sciences, Tehran, The Islamic Republic of Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Esmaeili","sequence":"additional","affiliation":[{"name":"School of Medicine, Tehran University of Medical Sciences, Tehran, The Islamic Republic of Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-1025","authenticated-orcid":false,"given":"Ehsaneh","family":"Taheri","sequence":"additional","affiliation":[{"name":"Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, The Islamic Republic of Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armita","family":"Mahdavi-Gorabi","sequence":"additional","affiliation":[{"name":"Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, The Islamic Republic of Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Rajabnia","sequence":"additional","affiliation":[{"name":"Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, The Islamic Republic of Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Djalalinia","sequence":"additional","affiliation":[{"name":"Non-Communicable Diseases Research Center, Tehran University of Medical Sciences, Tehran, The Islamic Republic of Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Goodarzi","sequence":"additional","affiliation":[{"name":"Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, The Islamic Republic of Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2018-9368","authenticated-orcid":false,"given":"Amir","family":"Kasaeian","sequence":"additional","affiliation":[{"name":"Research Center for Chronic Inflammatory Diseases, Tehran University of Medical Sciences, Tehran, The Islamic Republic of Iran"},{"name":"Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, The Islamic Republic of Iran"},{"name":"Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, The Islamic Republic of Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Shadab","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9465-7588","authenticated-orcid":false,"given":"Mostafa","family":"Qorbani","sequence":"additional","affiliation":[{"name":"Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, The Islamic Republic of Iran"},{"name":"Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, The Islamic Republic of Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"2026070902001860000_16.4.e111933.1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520"},{"key":"2026070902001860000_16.4.e111933.2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"2026070902001860000_16.4.e111933.3","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431"},{"key":"2026070902001860000_16.4.e111933.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.029"},{"key":"2026070902001860000_16.4.e111933.5","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-42398-w","article-title":"A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis","volume":"14","author":"Newsome","year":"2023","journal-title":"Nat Commun"},{"key":"2026070902001860000_16.4.e111933.6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/liv.14910","article-title":"Natural history of NASH","volume":"41 Suppl 1","author":"Armandi","year":"2021","journal-title":"Liver Int"},{"key":"2026070902001860000_16.4.e111933.7","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323"},{"key":"2026070902001860000_16.4.e111933.8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00535-022-01860-0","article-title":"Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD","volume":"57","author":"Ampuero","year":"2022","journal-title":"J Gastroenterol"},{"key":"2026070902001860000_16.4.e111933.9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070902001860000_16.4.e111933.10","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13727","article-title":"Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta-analysis of randomized controlled trials","volume":"25","author":"Wang","year":"2024","journal-title":"Obes Rev"},{"key":"2026070902001860000_16.4.e111933.11","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000843"},{"key":"2026070902001860000_16.4.e111933.12","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s13679-024-00574-z","article-title":"Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD","volume":"13","author":"Abdelhameed","year":"2024","journal-title":"Curr Obes Rep"},{"key":"2026070902001860000_16.4.e111933.13","first-page":"425","article-title":"Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials","volume":"84","author":"Wang","year":"2024","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026070902001860000_16.4.e111933.14","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2024.100593","article-title":"Comparative Efficacy of NAFLD Therapies and Biomarker Associations: A Meta-Analysis Based on Liver Fat Content","volume":"4","author":"Zhu","year":"2025","journal-title":"Gastro Hep Adv"},{"key":"2026070902001860000_16.4.e111933.15","doi-asserted-by":"crossref","first-page":"156043","DOI":"10.1016\/j.metabol.2024.156043","article-title":"Comparative efficacy of THR-\u03b2 agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis","volume":"161","author":"Lin","year":"2024","journal-title":"Metab Clin Exp"},{"key":"2026070902001860000_16.4.e111933.16","doi-asserted-by":"crossref","DOI":"10.1111\/jebm.70002","article-title":"Clinical Assessment of Common Medications for Nonalcoholic Fatty Liver Disease: A Systematic Review and Bayesian Network Meta-Analysis","volume":"18","author":"Shi","year":"2025","journal-title":"J Evid Based Med"},{"key":"2026070902001860000_16.4.e111933.17","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis","volume":"82","author":"Souza","year":"2025","journal-title":"Hepatology"},{"key":"2026070902001860000_16.4.e111933.18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/HEP.0000000000001028","article-title":"Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis","volume":"83","author":"Koh","year":"2026","journal-title":"Hepatology"},{"key":"2026070902001860000_16.4.e111933.19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cgh.2025.03.003","article-title":"Change in cT1 Following Interventions in MASLD: A Systematic Review and Meta-Analysis","volume":"24","author":"Andersson","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070902001860000_16.4.e111933.20","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001294","article-title":"Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content-Systematic review and network meta-analysis","volume":"83","author":"Huang","year":"2026","journal-title":"Hepatology"},{"key":"2026070902001860000_16.4.e111933.21","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1097\/HEP.0000000000001372","article-title":"Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content","volume":"83","author":"Romero-G\u00f3mez","year":"2026","journal-title":"Hepatology"},{"key":"2026070902001860000_16.4.e111933.22","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep4.1678","article-title":"coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment","volume":"5","author":"Clearfield","year":"2021","journal-title":"Hepatol Commun"},{"key":"2026070902001860000_16.4.e111933.23","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J Hepatol"},{"key":"2026070902001860000_16.4.e111933.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274406","article-title":"Comparative efficacy and acceptability of non-pharmacological interventions in fibromyalgia: Protocol for a network meta-analysis","volume":"17","author":"Souza","year":"2022","journal-title":"PLoS One"},{"key":"2026070902001860000_16.4.e111933.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-058102","article-title":"Pharmacological and non-pharmacological interventions for adults with ADHD: protocol for a systematic review and network meta-analysis","volume":"12","author":"Cortese","year":"2022","journal-title":"BMJ Open"},{"key":"2026070902001860000_16.4.e111933.26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24376"},{"key":"2026070902001860000_16.4.e111933.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"2026070902001860000_16.4.e111933.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.07.003"},{"key":"2026070902001860000_16.4.e111933.29","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30974"},{"key":"2026070902001860000_16.4.e111933.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.11.026"},{"key":"2026070902001860000_16.4.e111933.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2026070902001860000_16.4.e111933.32","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-024-02356-6","article-title":"Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis","volume":"24","author":"Abbas","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"2026070902001860000_16.4.e111933.33","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2020.100684","article-title":"Intention-to-treat analysis when only a baseline value is available","volume":"20","author":"Twisk","year":"2020","journal-title":"Contemp Clin Trials Commun"},{"key":"2026070902001860000_16.4.e111933.34","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026070902001860000_16.4.e111933.35","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026070902001860000_16.4.e111933.36","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-30","article-title":"Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference?","volume":"14","author":"Takeshima","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026070902001860000_16.4.e111933.37","doi-asserted-by":"crossref","first-page":"394","DOI":"10.11124\/JBIES-23-00368","article-title":"Comparisons of the mean differences and standardized mean differences for continuous outcome measures on the same scale","volume":"22","author":"Jing","year":"2024","journal-title":"JBI Evid Synth"},{"key":"2026070902001860000_16.4.e111933.38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjos-2020-100074","article-title":"Comparison of commonly used methods in random effects meta-analysis: application to preclinical data in drug discovery research","volume":"5","author":"Tanriver-Ayder","year":"2021","journal-title":"BMJ Open Sci"},{"key":"2026070902001860000_16.4.e111933.39","unstructured":"Cochrane Methods . Random-effects meta-analysis methods for Intervention Reviews. 2024. Available: https:\/\/methods.cochrane.org\/methods-cochrane\/random-effects-meta-analysis-methods-intervention-reviews"},{"key":"2026070902001860000_16.4.e111933.40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"2026070902001860000_16.4.e111933.41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212650","article-title":"Description of network meta-analysis geometry: A metrics design study","volume":"14","author":"Tonin","year":"2019","journal-title":"PLoS One"},{"key":"2026070902001860000_16.4.e111933.42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010919","article-title":"Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis","volume":"6","author":"Furukawa","year":"2016","journal-title":"BMJ Open"},{"key":"2026070902001860000_16.4.e111933.43","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-024-03322-1","article-title":"Low awareness of the transitivity assumption in complex networks of interventions: a systematic survey from 721 network meta-analyses","volume":"22","author":"Spineli","year":"2024","journal-title":"BMC Med"},{"key":"2026070902001860000_16.4.e111933.44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta\u2010analysis: concepts and models for multi\u2010arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"2026070902001860000_16.4.e111933.45","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dys222"},{"key":"2026070902001860000_16.4.e111933.46","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-13-35","article-title":"A graphical tool for locating inconsistency in network meta-analyses","volume":"13","author":"Krahn","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"2026070902001860000_16.4.e111933.47","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3767"},{"key":"2026070902001860000_16.4.e111933.48","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"2026070902001860000_16.4.e111933.49","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2022-300457"},{"key":"2026070902001860000_16.4.e111933.50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"2026070902001860000_16.4.e111933.51","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6321"},{"key":"2026070902001860000_16.4.e111933.52","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074495","article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich","year":"2023","journal-title":"BMJ"},{"key":"2026070902001860000_16.4.e111933.53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"2026070902001860000_16.4.e111933.54","doi-asserted-by":"crossref","first-page":"111276","DOI":"10.1016\/j.jclinepi.2024.111276","article-title":"The GRADE Working Group and CINeMA approaches provided inconsistent certainty of evidence ratings for a network meta-analysis of opioids for chronic noncancer pain","volume":"169","author":"Noori","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"2026070902001860000_16.4.e111933.55","unstructured":"StataCorp . Stata statistical software: release 18. College Station, TX: StataCorp LLC, 2023."},{"key":"2026070902001860000_16.4.e111933.56","unstructured":"R Core Team . R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2021."},{"key":"2026070902001860000_16.4.e111933.57","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v106.i02"},{"key":"2026070902001860000_16.4.e111933.58","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-111933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:00:46Z","timestamp":1783587646000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-111933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":58,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,8]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjopen-2025-111933"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-111933","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}